July 20, 2023—Siemens Healthineers announced that its Atellica CI analyzer for immunoassay and clinical chemistry testing has received FDA clearance and is now available in many countries.
The Atellica CI analyzer makes it possible for standalone and satellite labs to have the same reagents, consumables, and intelligent software as the company’s flagship Atellica Solution. The analyzer features random access sampling, microvolume aspiration, and automatic maintenance and quality control scheduling to enable labs to deliver more predictable sample turnaround times. Chemistry and immunoassay engines run independently so throughput is not compromised if one of the two needs to stop. More than 50 assays can deliver results in less than 14 minutes.
“Labs today need testing instrumentation and informatics that can easily keep pace with rapidly changing testing demands as they occur,” Sharon Bracken, head of diagnostics for Siemens, said in a press statement. “This next-generation laboratory analyzer anticipates workflow bottlenecks, mitigates them proactively, and delivers insights based on data that help laboratory staff do their job more effectively and efficiently.”
The analyzer is equipped with the Atellica Laboratory Evaluation Suite to deliver inspection-ready reports that help labs meet accreditation guidelines. User authentication, role-based authorizations, and audit trails are available for increased security.